Regencell Bioscience Investors Face June 23 Deadline in Fraud Suit
Investors who incurred financial losses holding Regencell Bioscience Holdings Limited shares between October 2024 and October 2025 have until June 23, 2026, to file as lead plaintiffs in a pending class action lawsuit. The litigation seeks to address alleged misrepresentations regarding the company's exposure to market volatility and regulatory scrutiny.
The complaint filed by Glancy Prongay Wolke & Rotter LLP claims that Regencell failed to inform shareholders about vulnerabilities to market manipulation and the subsequent risks to their investments. According to the filing, the company’s public statements regarding its business operations lacked a reasonable basis, leaving investors exposed to significant financial, legal, and reputational harm throughout the specified period.
Those seeking to participate in the action or inquire about their legal standing are directed to contact attorney Charles Linehan at the firm’s Los Angeles office. While investors may choose to retain their own counsel, those who do not take action will remain as absent class members. The firm emphasizes that this legal window is time-sensitive, requiring potential lead plaintiffs to register their interest before the June 23 deadline.
Comments (0)
No comments yet. Be the first!